Pharma M&A remains robust

摘要

AFTER SEVERAL years of relatively high dollar values,M&A volume in the pharmaceutical industry appears to be quieting down in 2005.Yet activity remains robust as companies turn to smaller,more targeted deals rather than the mega-mergers seen in years past.Once the darling of the investment community,the pharmaceutical industry has recently seen negative business trends start to outweigh positive ones."This is an industry in turmoil,"says Peter Young,president of investment bank Young & Partners,which recently completed a report on strategic and M&A trends in the pharmaceutical industry.